Compare Mercadolibre Inc (MELI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Novo Nordisk A/S — how do they compare? Mercadolibre Inc trades at $1,869.72 (market cap $98.35B), while Novo Nordisk A/S trades at $46.26 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.1× Mercadolibre Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| MELI | NVO | |
|---|---|---|
Market Cap | $98.35B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.51K | $63.98 |
52-Week Low | $1.55K | $35.29 |
Enterprise Value | $106.00B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,876, up 2.83% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 EPS of $9.19, beating estimates, while revenue grew 50% year-over-year to exceed $10 billion for the first time. Analyst consensus remains strongly bullish with 23 buy ratings and a $2,150 price target, though margin compression from strategic investments has tempered near-term profit growth.
MELI's growth-first strategy is driving market share gains but pressuring margins, creating a tension between rapid expansion and profitability. The stock offers significant upside to analyst targets but faces execution risks from increased competition and macroeconomic volatility in Latin America. Long-term investors may find value in the ecosystem growth, while short-term volatility could persist amid margin concerns.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
